![]() |
|
Names | |
---|---|
IUPAC name
Methyl (E)-2-((1′S,6′S,7′S,8a′S)-6'-ethyl-4-methoxy-3-oxo-3',5',6',7',8',8a'-hexahydro-2′H-spiro[indoline-2,1'-indolizin]-7'-yl)-3-methoxyacrylate
|
|
Other names
Spiro[2H-indole-2,1'(5′H)-indolizine]-7'-acetic acid, 6'-ethyl-1,2',3,3',6',7',8',8'a-octahydro-4-methoxy-α-(methoxymethylene)-3-oxo-, methyl ester, (αE,2S,6′S,7′S,8′aS)
|
|
Identifiers | |
3D model (Jmol)
|
|
ChemSpider | |
PubChem CID
|
|
|
|
|
|
Properties | |
C23H30N2O5 | |
Molar mass | 414.50 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Mitragynine pseudoindoxyl is a rearrangement product of 7-hydroxymitragynine. It is an analgesic being more potent than morphine and about as potent as enkephalin.
Mitragynine pseudoindoxyl is a μ opioid receptor agonist and δ opioid receptor antagonist and acts as a G-Protein biased agonist at μ opioid receptors and possesses a favourable side effect profile compared to conventional opioids.